What's New

  • BCAN Announces 2016 Young Investigator Awardees

    The Bladder Cancer Advocacy Network (BCAN) has announced the recipients of the 2016 Young Investigator Awards. The Young Investigator Awards fund researchers in basic, translational, clinical, epidemiologic, bio-engineering or any other scientific or research field. Recipients must be working in a research environment capable of supporting transformational bladder cancer research. The Stephen Hale Gushée Young Investigator Award will support Kent William Mouw, M.D., Ph.D. of Dana-Farber Cancer Institute, for his research “Identifying Genomic Determinants of Chemoradiotherapy Response in Muscle-Invasive Bladder Cancer.” Dr. Mouw’s study will leverage new genomic techniques to better understand how these biomarkers can benefit muscle invasive bladder cancer…

  • Nurses Opinion “Clinical Trials Rewarding Beyond Words”

    We had worked on the IMvigor 210 trial for two years, so it was an amazing moment for me when TecentriqTM (atezolizumab) was approved in May of this year.

  • One Woman’s Story about Dragon Boats, Clinical Trials and Immunotherapy

    With the recent approval of TecentriqTM BCAN spoke to Susan from Ohio, about her experience on the clinical trial.


Upcoming Events


  • Bladder cancer is the fifth most commonly diagnosed cancer in the U.S.
  • Nearly 77,000 new cases of bladder cancer are expected to be diagnosed in 2016.
  • More than 16,000 people will die from the disease this year alone.
  • Bladder cancer is three times more common in men than in women.
  • One in 42 people will be diagnosed with bladder cancer during their lifetime.
Click here for more details